4 research outputs found
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.
BACKGROUND: The ongoing Ebola outbreak led to accelerated efforts to test vaccine candidates. On the basis of a request by WHO, we aimed to assess the safety and immunogenicity of the monovalent, recombinant, chimpanzee adenovirus type-3 vector-based Ebola Zaire vaccine (ChAd3-EBO-Z).
METHODS: We did this randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a trial at the Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Participants (aged 18-65 years) were randomly assigned (2:2:1), via two computer-generated randomisation lists for individuals potentially deployed in endemic areas and those not deployed, to receive a single intramuscular dose of high-dose vaccine (5 × 10(10) viral particles), low-dose vaccine (2·5 × 10(10) viral particles), or placebo. Deployed participants were allocated to only the vaccine groups. Group allocation was concealed from non-deployed participants, investigators, and outcome assessors. The safety evaluation was not masked for potentially deployed participants, who were therefore not included in the safety analysis for comparison between the vaccine doses and placebo, but were pooled with the non-deployed group to compare immunogenicity. The main objectives were safety and immunogenicity of ChAd3-EBO-Z. We did analysis by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT02289027.
FINDINGS: Between Oct 24, 2014, and June 22, 2015, we randomly assigned 120 participants, of whom 18 (15%) were potentially deployed and 102 (85%) were non-deployed, to receive high-dose vaccine (n=49), low-dose vaccine (n=51), or placebo (n=20). Participants were followed up for 6 months. No vaccine-related serious adverse events were reported. We recorded local adverse events in 30 (75%) of 40 participants in the high-dose group, 33 (79%) of 42 participants in the low-dose group, and five (25%) of 20 participants in the placebo group. Fatigue or malaise was the most common systemic adverse event, reported in 25 (62%) participants in the high-dose group, 25 (60%) participants in the low-dose group, and five (25%) participants in the placebo group, followed by headache, reported in 23 (57%), 25 (60%), and three (15%) participants, respectively. Fever occurred 24 h after injection in 12 (30%) participants in the high-dose group and 11 (26%) participants in the low-dose group versus one (5%) participant in the placebo group. Geometric mean concentrations of IgG antibodies against Ebola glycoprotein peaked on day 28 at 51 μg/mL (95% CI 41·1-63·3) in the high-dose group, 44·9 μg/mL (25·8-56·3) in the low-dose group, and 5·2 μg/mL (3·5-7·6) in the placebo group, with respective response rates of 96% (95% CI 85·7-99·5), 96% (86·5-99·5), and 5% (0·1-24·9). Geometric mean concentrations decreased by day 180 to 25·5 μg/mL (95% CI 20·6-31·5) in the high-dose group, 22·1 μg/mL (19·3-28·6) in the low-dose group, and 3·2 μg/mL (2·4-4·9) in the placebo group. 28 (57%) participants given high-dose vaccine and 31 (61%) participants given low-dose vaccine developed glycoprotein-specific CD4 cell responses, and 33 (67%) and 35 (69%), respectively, developed CD8 responses.
INTERPRETATION: ChAd3-EBO-Z was safe and well tolerated, although mild to moderate systemic adverse events were common. A single dose was immunogenic in almost all vaccine recipients. Antibody responses were still significantly present at 6 months. There was no significant difference between doses for safety and immunogenicity outcomes. This acceptable safety profile provides a reliable basis to proceed with phase 2 and phase 3 efficacy trials in Africa.
FUNDING: Swiss State Secretariat for Education, Research and Innovation (SERI), through the EU Horizon 2020 Research and Innovation Programme
A weight-of-evidence framework for assessing sediment (or other) contamination:improving certainty in the decision-making process
Annealing effect on the dc transport mechanism in dysprosium oxide films grown on Si substrates
The significance of preschool behaviour problems for adjustment in later life
‘A child is born into a world of phenomena all equal in their power to enslave. It sniffs, it sucks — it strokes its eyes over the whole uncomfortable range. Suddenly, one strikes. Why? Moments snap together like magnets, forging a chain of shackles. Why? I can trace them. I can even with time pull them apart again. But why at the start they were ever magnetized at all —just those particular moments of experience and no others — I don't know. And nor does anyone else.’ from Equus by Schaffer (1974). Quoted in Chess, S. and Thomas, A. (1984)Origins and Evolution of Behaviour Disorders: from infancy to early adult life. Brunner Mazel, NY. The discussion of the significance of preschool behaviour problems for later adjustment begins by grounding the issue in the wider theoretical framework of developmental psychology. Transactionalismis identified as a global theory which now governs our understanding of developmental processes. It is shown to have a powerful explanatory value in relation to the long‐term effects of early adjustment problems. Longitudinal studies are reviewed and the development, maintenance and conversion of early problems (or indeed their disappearance or moderation) can be identified as transactional processes. The concept of risk and resilience are of central importance; some individuals show ‘competence’ and resist adversity but establishing why is beset with methodological and conceptual problems which may obscure actual vulnerability or misconstrue risk variables. Finally, research is found to be of limited value which does not address and explore the processes and mechanisms underlying resilience. A recent review of the impact of maternal depression on children exemplifies a transactional approach to understanding behavioural problems and also addresses the demand for a description of mechanisms involved. However, the issue of risk remains a major challenge